Proteomic identification of potential susceptibility factors in drug-induced liver disease

被引:49
|
作者
Welch, KD [1 ]
Wen, B
Goodlett, DR
Yi, EC
Lee, H
Reilly, TP
Nelson, SD
Pohl, LR
机构
[1] NHLBI, Mol & Cellular Toxicol Sect, Lab Mol Immunol, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[2] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
[3] Inst Syst Biol, Seattle, WA 98103 USA
关键词
D O I
10.1021/tx050011b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug-induced liver disease (DILD) causes significant morbidity and mortality and impairs new drug development. Currently, no known criteria can predict whether a drug will cause DILD or what risk factors make an individual susceptible. Although it has been shown in mouse studies that the disruption of key regulatory factors, such as cyclooxygenase-2 (COX-2), interleukin (IL)-6, and IL-10, increased susceptibility to DILD caused by acetaminophen (APAP), no single factor seems to be absolute. As an approach to better understand the multifactorial basis of DILD, we compared the hepatic proteome of mice that are resistant (SJL) and susceptible (C57Bl/6) to APAP-induced liver disease (AILD), using solution-based isotope-coded affinity tag (ICAT) liquid chromatography mass spectrometry. Several novel factors were identified that were more highly expressed in the livers of SJL mice, including those involved in stress response, cell proliferation and tissue regeneration, and protein modification, implicating these proteins as potential hepatoprotective factors. There was also a selective loss of several mitochondrial proteins from the livers of the susceptible C57Bl/6 mice, suggesting that the loss of functional mitochondria may indeed play a role in AILD. These findings indicate that comparative hepatic proteomic analyses of susceptible and resistant mouse strains may provide a global approach for identifying potential risk factors and mechanistic pathways responsible for DILD.
引用
收藏
页码:924 / 933
页数:10
相关论文
共 50 条
  • [1] Proteomic identification of susceptibility factors in drug-induced liver disease (DILD)
    Welch, KD
    Reilly, TP
    Wen, B
    Goodlett, DR
    Yi, EC
    Lee, H
    Nelson, SD
    Pohl, LR
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 : 228 - 228
  • [2] In search of susceptibility factors for idiosyncratic drug-induced liver injury
    Reilly, TP
    [J]. DRUG METABOLISM REVIEWS, 2002, 34 : 44 - 44
  • [3] Drug-Induced Liver Disease
    Kim, Jiwon W.
    Hattori, Akiko
    Phongsamran, Paula V.
    [J]. CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2010, 22 (03) : 323 - +
  • [4] Drug-induced liver disease
    Shivakumar Chitturi
    Geoffrey C. Farrell
    [J]. Current Treatment Options in Gastroenterology, 2000, 3 (6) : 457 - 462
  • [5] DRUG-INDUCED LIVER DISEASE
    不详
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 191 (10): : 853 - &
  • [6] Drug-induced liver disease
    Lewis, JH
    Ahmed, M
    Shobassy, A
    Palese, C
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2006, 22 (03) : 223 - 233
  • [7] Drug-Induced Liver Disease
    Davern, Timothy J.
    [J]. CLINICS IN LIVER DISEASE, 2012, 16 (02) : 231 - +
  • [8] Drug-induced liver disease
    Strohmeyer, G
    Weik, C
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1999, 37 (05): : 367 - 378
  • [9] Drug-induced liver disease
    Lewis, JH
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2002, 18 (03) : 307 - 313
  • [10] Drug-induced liver disease
    Lewis, JH
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (05) : 1275 - +